Histone deacetylase inhibition: a novel approach to cancer treatment

por Cheson, B D
Publicado 2006

Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma

por Assouline, S E, Chang, J, Cheson, B D, Rifkin, R, Hamburg, S, Reyes, R, Hui, A-M, Yu, J, Gupta, N, Di Bacco, A, Shou, Y, Martin, P
Publicado 2014